Professor's little helper

The use of cognitive-enhancing drugs by both ill and healthy individuals raises ethical questions that should not be ignored, argue Barbara Sahakian and Sharon Morein-Zamir.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    Comas-Herrera, A., Wittenberg, R., Pickard, L., Knapp, M. & MRC-CFAS. PSSRU Discussion Paper 1728 (2003).

  2. 2

    Wu, E. Q. et al. J. Clin. Psychiatry 66, 1122–1129 (2005).

  3. 3

    Davidson, M. & Keefe, R. S. Schizophr. Res. 17, 123–129 (1995).

  4. 4

    Morein-Zamir, S., Turner, D. C. & Sahakian, B. J. Schizophr. Bull. doi:10.1093/schbul/sbm090 (2007).

  5. 5

    Turner, D. C. et al. Neuropsychopharmacol. 29, 1363–1373 (2004).

  6. 6

    Barkley, R. A. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment 3rd edn (Guilford, New York, 2006).

  7. 7

    Swanson, J. M. et al. J. Am. Acad. Child Adolesc. Psychiatry 46, 1015–1027 (2007).

  8. 8

    Farah, M. J. et al. Nature Rev. Neurosci. 5, 421–425 (2004).

  9. 9

    Lorist, M. M. & Tops, M. Brain Cogn. 53, 82–94 (2003).

  10. 10

    Elliott, R. et al. Psychopharmacol. 131, 196–206 (1997).

Download references

Author information



Ethics declarations

Competing interests

Barbara Sahakian consults for several pharmaceutical companies and for Cambridge Cognition. She also has shares in CeNeS.

Additional information

Join the discussion at:

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sahakian, B., Morein-Zamir, S. Professor's little helper. Nature 450, 1157–1159 (2007).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.